drugset
drugset / Trial / NCT05806359

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

NCT05806359 ↗

Phase 1 Completed 33 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

Timeline

Start
2023-03-31
Primary completion
2023-08-14
Completion
2023-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicamtiv Small molecule — —

Indications

No indication recorded.